2 most recent filings and news items mentioning SGMT. Updated every 60 seconds.
LeadershipJul 21, 2026Neutral
Sagimet Biosciences presented data related to its innovative metabolic dysfunction pipeline and engaged investors, despite noting standard risks regarding clinical trial timelines and regulatory approvals.
View filing at SEC.gov →
OtherJun 3, 2026Neutral
Sagimet Biosciences issued an exhibit detailing the terms of performance-based restricted stock unit awards to employees under its 2023 Stock Option and Incentive Plan. The PSUs vest based on performance milestones and continued service, with forfeiture provisions if employment t
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.